Brokerages Set DexCom, Inc. (NASDAQ:DXCM) PT at $99.29

DexCom, Inc. (NASDAQ:DXCM) has earned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $98.41.

DXCM has been the subject of several research reports. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Citigroup upped their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th.

Insider Buying and Selling

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,342 shares of company stock valued at $3,628,069. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Large investors have recently modified their holdings of the stock. NewEdge Advisors LLC lifted its stake in DexCom by 18.3% in the second quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock worth $1,023,000 after acquiring an additional 1,393 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its position in shares of DexCom by 4.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after purchasing an additional 162 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of DexCom during the second quarter worth $1,395,000. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in DexCom by 533.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock valued at $4,140,000 after buying an additional 30,743 shares during the last quarter. Finally, Centaurus Financial Inc. raised its stake in DexCom by 31.5% in the second quarter. Centaurus Financial Inc. now owns 2,612 shares of the medical device company’s stock valued at $296,000 after buying an additional 625 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $87.46 on Friday. The company has a fifty day simple moving average of $80.95 and a 200-day simple moving average of $75.77. The firm has a market capitalization of $34.16 billion, a price-to-earnings ratio of 52.37, a PEG ratio of 2.23 and a beta of 1.14. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.